Like the Senate, the House has passed a bill that would give the FDA more authority to ensure drug safety by requiring manufacturers to conduct postmarketing surveillance studies; demand more user fees; and other measures. Since H.R. 2900 contains some provisions that are different from S. 1082, with the House version considered the stronger one, a conference committee will now have to come up with a new bill that both houses can approve before it is sent to the President for signature.
